BioXcel Therapeutics Inc (BTAI) — Financial Flexibility Index
BioXcel Therapeutics Inc (BTAI) has a Financial Flexibility Index of -0.08x as of March 2026. Free cash flow of $-11.81 Million (operating CF $-11.81 Million minus capex $0.00) represents 0% of total liabilities ($139.57 Million). Check BTAI goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BioXcel Therapeutics Inc Financial Flexibility Index (2015–2025)
Historical Financial Flexibility Index trend for BioXcel Therapeutics Inc across 11 annual periods. For the full cash flow conversion analysis, see how efficiently does BioXcel Therapeutics Inc generate cash.
Annual Financial Flexibility Index for BioXcel Therapeutics Inc (2015–2025)
Year-by-year free cash flow to debt coverage for BioXcel Therapeutics Inc. Explore BioXcel Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.41x | $-57.62 Million | $-57.62 Million | $140.38 Million | ▲ +25.1% |
| 2024 | -0.55x | $-72.03 Million | $-72.03 Million | $131.44 Million | ▲ +54.0% |
| 2023 | -1.19x | $-154.99 Million | $-155.01 Million | $130.21 Million | ▼ -13.6% |
| 2022 | -1.05x | $-135.20 Million | $-135.34 Million | $129.08 Million | ▲ +77.2% |
| 2021 | -4.60x | $-81.71 Million | $-82.15 Million | $17.77 Million | ▲ +7.8% |
| 2020 | -4.99x | $-66.03 Million | $-66.35 Million | $13.24 Million | ▼ -79.3% |
| 2019 | -2.78x | $-26.41 Million | $-27.28 Million | $9.50 Million | ▲ +1.6% |
| 2018 | -2.83x | $-13.17 Million | $-13.51 Million | $4.66 Million | ▼ -255.8% |
| 2017 | -0.79x | $-1.86 Million | $-2.20 Million | $2.34 Million | ▲ +79.6% |
| 2016 | -3.90x | $-1.29 Million | $-1.29 Million | $331.00K | ▼ -144.5% |
| 2015 | -1.59x | $-279.00K | $-280.00K | $175.00K | — |